Venetoclax moves us closer towards zero lives lost to blood cancer
- Advocacy and policy
- Research
Tag: Advocacy and policy
National Action Plan represents Australian first opportunity to achieve zero lives lost to blood cancer by 2035
- Advocacy and policy
- Media releases
Daratumumab – first new myeloma agent PBAC-recommended in years
The drug has received a positive recommendation for PBS listing.
- Advocacy and policy
- Myeloma
- Treatments and side-effects
Breaking barriers: At the table with best and brightest
Deb Henderson shares her story to help us mark Blood Cancer Awareness Month. Deb has blood cancer and is also a member of the Blood Cancer Taskforce.
- Advocacy and policy
- Chronic lymphocytic leukaemia
Breaking barriers: Sharyn’s 130,000km journey to treatment
Blood cancer survivor Sharyn Polce has experienced first-hand the ‘postcode lottery’ of treatment
- Advocacy and policy
You’re a part of the blood cancer revolution!
This Blood Cancer Awareness Month, find out how you can help people with blood cancer get the treatments they need.
- Advocacy and policy
- Our supporters
Blood Cancer Taskforce develops national plan
The Blood Cancer Taskforce has brought the Australian blood cancer community together to develop the first National Strategic Action Plan for Blood Cancer. Â
- Acute myeloid leukaemia
- Advocacy and policy
- Chronic myeloid leukaemia
Novel combination therapy now available for myeloma patients through PBS
The Leukaemia Foundation has welcomed news that a new novel combination therapy option will now be available to more myeloma patients through the Pharmaceutical Benefits Scheme (PBS).
- Advocacy and policy
- Media releases
- Myeloma
Meet the Blood Cancer Taskforce: Prof. Tim Hughes
Taskforce member Prof. Hughes is a researcher and haematologist.
- Advocacy and policy
Meet the Blood Cancer Taskforce: Carmel O’Kane
Taskforce member Carmel has been a cancer nurse for 24 years.
- Advocacy and policy
